Find the pharmaceutical Marketplace for latest API enquiries of Starch on PharmaCompass.com

PharmaCompass

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

SUPPLIERS

read-more
read-more

01

Roquette

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

Roquette

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

02

Anhui Sunhere Pharmaceutical Excip...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

Anhui Sunhere Pharmaceutical Excip...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Hunan ErKang Pharmaceutical Co Ltd

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

Hunan ErKang Pharmaceutical Co Ltd

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Micro Pellet

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

Micro Pellet

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Bluecraft Agro

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

Bluecraft Agro

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

GRAIN PROCESSING CORP

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

GRAIN PROCESSING CORP

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Japan Corn Starch Co. LTD

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

Japan Corn Starch Co. LTD

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Maple Biotech

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

Maple Biotech

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

S D Fine Chem Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

S D Fine Chem Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

COLORCON INC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Formnext Forum
Not Confirmed
arrow

COLORCON INC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Formnext Forum
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Asahi Kasei Corp

Japan

USDMF

arrow
ASC 2024
Not Confirmed

02

Asahi Kasei Corp

Japan

USDMF

arrow
ASC 2024
Not Confirmed

03

Colorcon

U.S.A

USDMF

arrow
ASC 2024
Not Confirmed

04

Grain Processing Corp

U.S.A

USDMF

arrow
ASC 2024
Not Confirmed

04

05

ASC 2024
Not Confirmed

06

Ingredion Inc

U.S.A

USDMF

arrow
ASC 2024
Not Confirmed

07

Ingredion Inc

U.S.A

USDMF

arrow
ASC 2024
Not Confirmed

07

ASC 2024
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 15712

Submission : 2001-11-12

Status : Active

Type : IV

blank

08

ASC 2024
Not Confirmed

08

ASC 2024
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 28266

Submission : 2014-05-06

Status : Active

Type : IV

blank

09

Micropellet

India

USDMF

arrow
ASC 2024
Not Confirmed

10

ASC 2024
Not Confirmed
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FINISHED DOSAGE FORMULATIONS

Upload your portfolio for free, ask us

FDF DOSSIERS SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

MEPENZOLATE BROMIDE

Drug : CANTIL

Dosage Form : SOLUTION; ORAL

Application Number : 10679

Country : US

Patented : No

Sanofi Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

MEPENZOLATE BROMIDE

Drug : CANTIL

Dosage Form : TABLET; ORAL

Application Number : 10679

Country : US

Patented : No

Sanofi Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

PRIMAQUINE PHOSPHATE

Drug : PRIMAQUINE

Dosage Form : TABLET; ORAL

Application Number : 8316

Country : US

Patented : No

Sanofi Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

TERIFLUNOMIDE

Drug : AUBAGIO

Dosage Form : TABLET; ORAL

Application Number : 202992

Country : US

Patented : Yes

Sanofi Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

HYDROCHLOROTHIAZIDE; IRBESARTAN

Drug : AVALIDE

Dosage Form : TABLET; ORAL

Application Number : 20758

Country : US

Patented : No

Sanofi Company Banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

IRBESARTAN

Drug : AVAPRO

Dosage Form : TABLET; ORAL

Application Number : 20757

Country : US

Patented : No

Sanofi Company Banner

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

CLOMIPHENE CITRATE

Drug : CLOMID

Dosage Form : TABLET; ORAL

Application Number : 16131

Country : US

Patented : No

Sanofi Company Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Dossiers

read-more
read-more

01

Dosage Form : TABLET

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : TABLET

USA
arrow
Formnext Forum
Not Confirmed

Route : BUCCAL

CAS : 9005258

UNII : NA

Potency Amount : 22.5

Potency Unit : MG

blank

02

Dosage Form : TABLET

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : TABLET

USA
arrow
Formnext Forum
Not Confirmed

Route : BUCCAL/SUBLINGUAL

CAS : 9005258

UNII : NA

Potency Amount : 14.19

Potency Unit : MG

blank

03

Dosage Form : INJECTION

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : INJECTION

USA
arrow
Formnext Forum
Not Confirmed

Route : INTRAMUSCULAR

CAS : 9005258

UNII : NA

Potency Amount : 0.6

Potency Unit : %

blank

04

Dosage Form : CAPSULE

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : CAPSULE

USA
arrow
Formnext Forum
Not Confirmed

Route : ORAL

CAS : 9005258

UNII : NA

Potency Amount : 605

Potency Unit : MG

blank

05

Dosage Form : CAPSULE, COATED, HARD GELATIN

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : CAPSULE, COATED, HARD GELATIN

USA
arrow
Formnext Forum
Not Confirmed

Route : ORAL

CAS : 9005258

UNII : NA

Potency Amount : 25

Potency Unit : MG

blank

06

Dosage Form : CAPSULE, DELAYED ACTION

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : CAPSULE, DELAYED ACTION

USA
arrow
Formnext Forum
Not Confirmed

Route : ORAL

CAS : 9005258

UNII : NA

Potency Amount : 43.5

Potency Unit : MG

blank

07

Dosage Form : CAPSULE, ENTERIC COATED PELLET...

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : CAPSULE, ENTERIC COATED PELLET...

USA
arrow
Formnext Forum
Not Confirmed

Route : ORAL

CAS : 9005258

UNII : NA

Potency Amount : 36.4

Potency Unit : MG

blank

08

Dosage Form : CAPSULE, HARD GELATIN

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : CAPSULE, HARD GELATIN

USA
arrow
Formnext Forum
Not Confirmed

Route : ORAL

CAS : 9005258

UNII : NA

Potency Amount : 33.5

Potency Unit : MG

blank

09

Dosage Form : CAPSULE, SOFT GELATIN

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : CAPSULE, SOFT GELATIN

USA
arrow
Formnext Forum
Not Confirmed

Route : ORAL

CAS : 9005258

UNII : NA

Potency Amount : 15.5

Potency Unit : MG

blank

10

Dosage Form : CAPSULE, SUSTAINED ACTION

STARCH
arrow
Formnext Forum
Not Confirmed

Dosage Form : CAPSULE, SUSTAINED ACTION

USA
arrow
Formnext Forum
Not Confirmed

Route : ORAL

CAS : 9005258

UNII : NA

Potency Amount : 65.2

Potency Unit : MG

blank
click full view

EXCIPIENTS BY APPLICATIONS

Click here to find the perfect excipient manufacturers by their capabilities

Fillers Diluents Binders

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGangwal Healthcare is powered by innovation, driving health, wellness & healing.

Grade : Oral

Category : Fillers, Diluents & Binders

click full view

Direct Compression

read-more
read-more

Co Processed Excipients

read-more
read-more

Disintegrants Superdisintegrants

read-more
read-more

Taste Masking

read-more
read-more

Chewable Orodispersible Aids

read-more
read-more

Controlled Modified Release

read-more
read-more

Thickeners And Stabilizers

read-more
read-more

Granulation

read-more
read-more

Coating Systems Additives

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination
The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   

Impressions: 1234

https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

#PharmaFlow by PHARMACOMPASS
12 Sep 2024

MARKET PLACE

Do you need sourcing support? Ask us

EXCIPIENTS

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty